Laura P. Masurovsky

Lead trial counsel in a series of litigations forming part of a worldwide patent enforcement program to protect rights directed to MPEG audio technology. All litigations concluded with worldwide settlements. The program reached more than 1,000 licensees.

Won a complete jury verdict for Avid on issues of inventorship and patent ownership affirmed by the Federal Circuit. Also obtained a finding of exceptional case, entitling Avid to an award of attorneys’ fees. The trial disposed of a series of suits by the AIA against numerous companies involved in scientific research relating to Alzheimer’s disease.

Lead counsel for Cumberland in ANDA litigation and breach of contract arbitration. Successful verdict and outcome in bench trial, arbitration, arbitration fee award, and on appeal.

Co-lead counsel for plaintiffs in consolidated ANDA cases involving Axiron®.

Lead trial counsel for S3 Graphics in litigation related to license and ownership rights to the patents-in-suit.

Represented Eli Lilly in a suit involving patent on NF-ĸB inhibition. Federal Circuit issued landmark en banc opinion on the written description requirement and reversed adverse trial court judgment.

Successfully represented Eli Lilly in district court and Federal Circuit against generic company with respect to osteoporosis drug Evista®. Two of three patent families in suit found valid and infringed at trial and on appeal. Also represented Eli Lilly in successful appeal regarding obtaining extension of thirty-month regulatory stay.

Led litigations for IP Global enforcing licensing program involving consumer electronics patent portfolio.

Represented Eli Lilly and Company in Hatch-Waxman patent litigation relating to osteoporosis drug Forteo®.

Representing Biogen in ANDA litigation against 27 generic drug manufacturers concerning Biogen’s Tecfidera® (dimethyl fumarate) product for the treatment of relapsing forms of multiple sclerosis.